Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care
Lead Research Organisation:
University College London
Department Name: UNLISTED
Abstract
Our aim is to reduce cancer deaths and the side effects associated with cancer treatments. We design clinical trials and other research studies that test several new approaches at the same time. This speeds up the evaluation of new therapies.
Cancer is becoming more common, especially in low and middle income countries (LMICs) where it is estimated that 70% of cancers and 80% of cancer deaths will occur in 2020. We focus on the need for more affordable and effective cancer treatments. This is also important for high income countries.
We test drugs that are already used for another disease. This is called repurposing. We also test whether radiotherapy, surgery and existing scanning techniques can be used in different and more efficient ways to improve the diagnosis and treatment of cancer. We will also test whether newer drugs (immuno–oncology) can be given for shorter periods of time with the same benefits and less side effects.
In the future we will work on: a) cancers that are common and cause many deaths in LMICs; b) cancers that are less common which makes it difficult to run clinical trials; and c) studies to prevent cancer. Running a clinical trial in these areas can be challenging and not many research groups work in these areas.
The impact of our work is recognised if the treatments we assess are recommended for patients by doctors because of our trials. Further impacts are to help increase research visibility and capacity in LMICs, including for example heling to develop Principal Investigators in countries. We also collect biological samples from trial participants and scientists evaluate them to increase our understanding of cancer.
Cancer is becoming more common, especially in low and middle income countries (LMICs) where it is estimated that 70% of cancers and 80% of cancer deaths will occur in 2020. We focus on the need for more affordable and effective cancer treatments. This is also important for high income countries.
We test drugs that are already used for another disease. This is called repurposing. We also test whether radiotherapy, surgery and existing scanning techniques can be used in different and more efficient ways to improve the diagnosis and treatment of cancer. We will also test whether newer drugs (immuno–oncology) can be given for shorter periods of time with the same benefits and less side effects.
In the future we will work on: a) cancers that are common and cause many deaths in LMICs; b) cancers that are less common which makes it difficult to run clinical trials; and c) studies to prevent cancer. Running a clinical trial in these areas can be challenging and not many research groups work in these areas.
The impact of our work is recognised if the treatments we assess are recommended for patients by doctors because of our trials. Further impacts are to help increase research visibility and capacity in LMICs, including for example heling to develop Principal Investigators in countries. We also collect biological samples from trial participants and scientists evaluate them to increase our understanding of cancer.
Technical Summary
Our aim is to improve cancer survival and decrease cancer morbidity by designing and implementing innovative late phase studies that have a major impact on clinical practice. We focus on adaptive trials that test more than one primary research hypothesis to increase efficiency including multi-arm multi-stage platforms, umbrella, and basket trial designs, primarily in the phase III setting.
Cancer incidence is increasing rapidly, and disproportionately so in low and middle income countries (LMICs) where it is estimated that 70% of cancers and 80% of cancer deaths will occur in 2020. This programme focusses on the need for affordable and less toxic therapies that can be implemented across a range of economic settings. We evaluate existing healthcare technologies (e.g. drug repurposing or rescheduling, established imaging techniques, surgery and radiotherapy) to optimise clinical efficacy and/or broaden the patient group that can benefit.
We address clinical questions others are unlikely to tackle, either due to a challenging clinical scenario, geographical setting, and/or lack of interest or support from the pharmaceutical industry. Consequently, and particularly in the future, we will focus on: a) cancers with a high incidence and mortality in LMICs; b) rarer and less common cancers; and c) prevention and early diagnosis as an affordable approach to improve outcomes. Integrated working with methodology colleagues enhances trial design, conduct and analysis, and facilitates the implementation of results.
Examples of drug repurposing projects include the evaluation of aspirin as an adjuvant therapy in common solid tumours and metformin as a potential anti-cancer therapy. Immuno-oncology projects are focussed on shorter and more affordable regimens and are underpinned by novel trial designs developed at the MRC CTU. Primary prevention cancer trials are long term projects; our aim is to conduct them efficiently, making optimal use of electronic health records.
We are developing an increasing network of investigators in LMICs - integral to this work is our capacity building activities in terms of education and mentorship in clinical research methodology, particularly in India. Impact is recognised by change in clinical practice and incorporation of the new clinical approach into international guidelines.
Maximising the potential between discovery science and applied research is key to our strategy with biological samples from trial participants analysed by cutting edge scientists and, where appropriate, results fed back into clinical practice and future trial designs. We are also building upon our trial work particularly in prostate cancer and our aspirin-related studies to establish repositories of trial data to facilitate meta-analyses.
Cancer incidence is increasing rapidly, and disproportionately so in low and middle income countries (LMICs) where it is estimated that 70% of cancers and 80% of cancer deaths will occur in 2020. This programme focusses on the need for affordable and less toxic therapies that can be implemented across a range of economic settings. We evaluate existing healthcare technologies (e.g. drug repurposing or rescheduling, established imaging techniques, surgery and radiotherapy) to optimise clinical efficacy and/or broaden the patient group that can benefit.
We address clinical questions others are unlikely to tackle, either due to a challenging clinical scenario, geographical setting, and/or lack of interest or support from the pharmaceutical industry. Consequently, and particularly in the future, we will focus on: a) cancers with a high incidence and mortality in LMICs; b) rarer and less common cancers; and c) prevention and early diagnosis as an affordable approach to improve outcomes. Integrated working with methodology colleagues enhances trial design, conduct and analysis, and facilitates the implementation of results.
Examples of drug repurposing projects include the evaluation of aspirin as an adjuvant therapy in common solid tumours and metformin as a potential anti-cancer therapy. Immuno-oncology projects are focussed on shorter and more affordable regimens and are underpinned by novel trial designs developed at the MRC CTU. Primary prevention cancer trials are long term projects; our aim is to conduct them efficiently, making optimal use of electronic health records.
We are developing an increasing network of investigators in LMICs - integral to this work is our capacity building activities in terms of education and mentorship in clinical research methodology, particularly in India. Impact is recognised by change in clinical practice and incorporation of the new clinical approach into international guidelines.
Maximising the potential between discovery science and applied research is key to our strategy with biological samples from trial participants analysed by cutting edge scientists and, where appropriate, results fed back into clinical practice and future trial designs. We are also building upon our trial work particularly in prostate cancer and our aspirin-related studies to establish repositories of trial data to facilitate meta-analyses.
Publications
Parker CC
(2022)
RADICALS-HD: Reflections before the Results are Known.
in Clinical oncology (Royal College of Radiologists (Great Britain))
Merrick S
(2023)
REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers.
in Contemporary clinical trials
Macnair A
(2023)
Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected data
in Contemporary Clinical Trials
Brown L
(2022)
Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT
in Efficacy and Mechanism Evaluation
Gillessen S
(2023)
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
in European Journal of Cancer
Vogl UM
(2022)
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings.
in European journal of cancer (Oxford, England : 1990)
Budde A
(2022)
Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma.
in European journal of cancer (Oxford, England : 1990)
Bouche G
(2023)
Testing alternative schedules of adjuvant immune checkpoint blockers - The need for well-designed clinical trials.
in European journal of cancer (Oxford, England : 1990)
Budde A
(2022)
Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma.
in European journal of cancer (Oxford, England : 1990)
Related Projects
Project Reference | Relationship | Related To | Start | End | Award Value |
---|---|---|---|---|---|
MC_UU_00004/01 | 01/04/2021 | 31/03/2026 | £5,186,000 | ||
MC_UU_00004/02 | Transfer | MC_UU_00004/01 | 01/04/2021 | 31/03/2026 | £4,446,000 |
MC_UU_00004/03 | Transfer | MC_UU_00004/02 | 01/04/2021 | 31/03/2026 | £4,999,000 |
MC_UU_00004/04 | Transfer | MC_UU_00004/03 | 01/04/2021 | 31/03/2026 | £5,315,000 |
MC_UU_00004/05 | Transfer | MC_UU_00004/04 | 01/04/2021 | 31/03/2026 | £3,107,000 |
MC_UU_00004/06 | Transfer | MC_UU_00004/05 | 01/04/2021 | 31/03/2026 | £2,889,000 |
MC_UU_00004/07 | Transfer | MC_UU_00004/06 | 01/04/2021 | 31/03/2026 | £2,369,000 |
MC_UU_00004/08 | Transfer | MC_UU_00004/07 | 01/04/2021 | 31/03/2026 | £2,270,000 |
MC_UU_00004/09 | Transfer | MC_UU_00004/08 | 01/04/2021 | 31/03/2026 | £2,160,000 |
Guideline Title | Covid Guidelines India |
Description | Anti-IL6 COVID-19 SR (PMID:34228774) CMGIG guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline |
Description | Anti-IL6 COVID-19 SR (PMID:34228774) ERS guideline 2022 |
Geographic Reach | Europe |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | IDSA Guidelines on the Treatment and Management of Patients with COVID-19 |
Description | Anti-IL6 COVID-19 SR (PMID:34228774) IDSA guideline 2022 |
Geographic Reach | North America |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Interim Clinical Commissioning Policy: IL-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 (adults) |
Description | Anti-IL6 COVID-19 SR (PMID:34228774) NHS guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Description | Associate PI webinar series |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic Bladder cancer |
Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2022 |
Geographic Reach | Europe |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.3.2022 Bladder Cancer |
Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2022 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic (2022) |
Description | Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2022 |
Geographic Reach | Europe |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 3.2022 |
Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2022 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022 |
Description | Cervix CTRT IPD (PMID: 19001332) GGPO guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2022 Cervical Cancer |
Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2022 (1) |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Cervical Cancer |
Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2023 (1) |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2022 Cervical Cancer |
Description | Cervix CTRT IPD (PMID:20091632) NCCN guideline 2022 (1) |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Cervical Cancer |
Description | Cervix CTRT IPD (PMID:20091632) NCCN guideline 2023 (1) |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022 |
Description | Cervix CTRT SR (PMID: 16034873) GGPO guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update |
Description | Cervix Neo CT IPD (PMID: 15106161) ASCO guideline 2022 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update |
Description | Cervix Neo CT SR (PMID:23235641) ASCO guideline 2022 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022 |
Description | Cervix Neo CT SR (PMID:23235641) GGPO guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Description | Citation of RADICALS in APCCC 2023 Consensus Statement |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical reviews |
Impact | RCT results improve management of patient care |
URL | https://doi.org/10.1016/j.eururo.2022.11.002 |
Guideline Title | EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer |
Description | Citation of RADICALS in EAU 2022 prostate cancer guidelines |
Geographic Reach | Europe |
Policy Influence Type | Citation in clinical guidelines |
Impact | Clinical trial should how improvements can be made to patient outcomes |
URL | https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelin... |
Guideline Title | EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer |
Description | Citation of STAMPDE in EAU 2022 prostate cancer guidelines |
Geographic Reach | Europe |
Policy Influence Type | Citation in clinical guidelines |
Impact | Clinical trial should how improvements can be made to patient outcomes |
URL | https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelin... |
Description | Citation of STAMPEDE in APCCC 2023 Consensus Statement |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical reviews |
Impact | RCT results improve management of patient care |
URL | https://doi.org/10.1016/j.eururo.2022.11.002 |
Guideline Title | National Comprehensive Cancer Network (NCCN) Guidelines® Insights: Prostate Cancer, Version 1.2023: Featured Updates to the NCCN Guidelines |
Description | Citation of STAMPEDE in NCCN Guidelines Insights: Prostate Cancer, Version 1.2023 |
Geographic Reach | North America |
Policy Influence Type | Citation in clinical guidelines |
Impact | Clinical trials results improve patient outcomes |
URL | https://doi.org/10.6004/jnccn.2022.0063 |
Guideline Title | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer (from European Society for Medical Oncology (ESMO), Singapore Society of Oncology (SSO), China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). |
Description | Citation of STAMPEDE in Pan-Asian adapted ESMO Prostate Cancer Guidelines |
Geographic Reach | Asia |
Policy Influence Type | Citation in clinical guidelines |
Impact | RCTs results improve patient care |
URL | https://www.esmoopen.com/article/S2059-7029(22)00138-7/fulltext |
Guideline Title | S3-Leitlinie endometrriumkarzinom V2.0 (2022) |
Description | Endometrial CT SR (PMID: 22895938) GGPO guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer |
Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2023 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update |
Description | Lung Adj CT IPD (PMID:25730344) ASCO guideline 2022 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update |
Description | Lung CT 95 IPD (PMID:7580546) ASCO guideline stage I-III NSCLC 2022 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2023 |
Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2023 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
Description | Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer |
Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2023 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
Description | Lung PORT IPD (PMID: 9690404) GGPO guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer |
Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2023 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update |
Description | Lung PORT IPD (PMID: 9690404; 23453644) ASCO guideline 2022 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
Description | Lung SC IPD (PMID: 18678835) GGPO guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer |
Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2023 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
Description | Lung SC IPD (PMID: 25730344) GGPO guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
Description | Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Practice Guidelines in Oncology v1.2023. Non-Small Cell Lung Cancer |
Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2023 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. V3.1 (2022) |
Description | Oesophagus RT IPD (PMID:16235286) GGPO guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Guidelines Version 5.2022 Esophageal and Esophagogastric Junction Cancers |
Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2022 (v5) |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | EAU Guideline: Prostate Cancer (2019) |
Description | Prostate Abi AD (PMID: 28800492) EAU guideline 2019 |
Geographic Reach | Europe |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | EAU Guideline: Prostate Cancer (2021) |
Description | Prostate Abi AD (PMID: 28800492) EAU guideline 2021 |
Geographic Reach | Europe |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | EAU Guideline: Prostate Cancer (2022) |
Description | Prostate Abi AD (PMID: 28800492) EAU guideline 2022 |
Geographic Reach | Europe |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Local Prostate Cancer |
Description | Prostate Artistic AD (PMID: 33002431) AHS guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2022) |
Description | Prostate Artistic AD (PMID: 33002431) AUA/ASTRO guideline 2022 |
Geographic Reach | North America |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | EAU Guideline: Prostate Cancer (2022) |
Description | Prostate Artistic AD (PMID: 33002431) EAU guideline 2022 |
Geographic Reach | Europe |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer |
Description | Prostate Artistic AD (PMID: 33002431) NCCN guideline 2023 V1 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | EAU Guideline: Prostate Cancer (2022) |
Description | Prostate CT SR (PMID: 26718929) EAU guideline 2022 |
Geographic Reach | Europe |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer |
Description | Prostate CT SR (PMID: 30826218) NCCN guideline 2023 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | EAU Guideline: Prostate Cancer (2022) |
Description | Prostate Network AD (PMID: 29788164) EAU guideline 2022 |
Geographic Reach | Europe |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | 2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer |
Description | Prostate RT AD (PMID: 30826218) CUA guideline 2022 |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | EAU Guideline: Prostate Cancer (2022) |
Description | Prostate RT AD (PMID: 30826218) EAU guideline 2022 |
Geographic Reach | Europe |
Policy Influence Type | Citation in clinical guidelines |
Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2022 Soft Tissue Sarcoma |
Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2022 (V2) |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Description | CRUK/06/001: PATCH: Prostate Adenocarcinoma: TransCutaneous Hormones - 2021 extension |
Amount | £592,034 (GBP) |
Funding ID | C471/A12443 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2021 |
End | 09/2024 |
Description | RADICALS extension (A7829/A6381) |
Amount | £325,000 (GBP) |
Funding ID | (A7829/A6381) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2020 |
End | 03/2023 |
Description | REFINE stage I/II funding, Jon Moulton |
Amount | £1,061,788 (GBP) |
Organisation | J P Moulton Charitable Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2020 |
End | 04/2024 |
Description | Research Careers Committee - Clinical Trial Fellowship - November 2021 - Dr Sophie Merrick |
Amount | £150,581 (GBP) |
Funding ID | RCCCTF-Nov21\100002 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2022 |
End | 12/2025 |
Title | PATCH trial sample storage |
Description | In PATCH, blood and urine samples were collected at randomisation and various time points during trial follow-up for consenting patients randomised up to end October 2013. Baseline blood samples for future research are also being collected in all consenting patients (before and after October 2013). Until September 2021, all samples were stored at Charing Cross Hospital Assay Laboratory. In September 2021, samples were transferred to the Biodock biobank in Nottingham. |
Type Of Material | Biological samples |
Year Produced | 2006 |
Provided To Others? | No |
Impact | These samples will be utilised in analyses to increase understanding of the underlying mechanisms for the potential benefits and adverse effects of the trial treatments, for example, for assessing changes in SHBG, oestrone/oestradiol ratio and bone biomarkers during time on treatment. |
Description | REFINE translational samples - storage and analysis (NIH) |
Organisation | National Institutes of Health (NIH) |
Department | National Cancer Institute (NCI) |
Country | United States |
Sector | Public |
PI Contribution | Within REFINE, blood samples are taken prior to each treatment administration. The aims are to better understand both the pharmacokinetics of immune checkpoint inhibitors and also the pharmacodynamics with respect to target efficacy between different frequencies of administration. These samples will initially be stored at Imperial College in the UK, before being transferred to Dr Cody Peer and Dr William Figg at the National Cancer Institute for analysis. |
Collaborator Contribution | The expertise of the NIH, and in particular Drs Peer and Figg, is key to the analysis of the trial samples, and the interpretation of the results. |
Impact | REFINE is in the final stages of set-up, so no outputs yet. |
Start Year | 2022 |
Description | Training the next generation of Indian clinical trialists |
Organisation | Christian Medical College, Vellore |
Country | India |
Sector | Academic/University |
PI Contribution | Have provided guidance, contributed to each aspect of the development of an Indian MSc (details below), visitied both Indian sites and taught on the MSc |
Collaborator Contribution | Worked together to develop and deliver an Indian MSc - details below Submitted a BC grant application to support exchanges of students and staff which was successful |
Impact | Secured funding from British Council - Going Global Partnerships India - Collaborative Grant Launch in Sept 2022 a two-year MSc in Clinical Research with specialisation in Clinical Trials at THSTI, India. Twelve students have been enrolled in the first batch. The degree will be awarded by RCB India. Multidisciplinary - clinicians, statisticians, clinical trialists |
Start Year | 2019 |
Description | Training the next generation of Indian clinical trialists |
Organisation | Translational Health Science And Technology Institute |
Country | India |
Sector | Public |
PI Contribution | Have provided guidance, contributed to each aspect of the development of an Indian MSc (details below), visitied both Indian sites and taught on the MSc |
Collaborator Contribution | Worked together to develop and deliver an Indian MSc - details below Submitted a BC grant application to support exchanges of students and staff which was successful |
Impact | Secured funding from British Council - Going Global Partnerships India - Collaborative Grant Launch in Sept 2022 a two-year MSc in Clinical Research with specialisation in Clinical Trials at THSTI, India. Twelve students have been enrolled in the first batch. The degree will be awarded by RCB India. Multidisciplinary - clinicians, statisticians, clinical trialists |
Start Year | 2019 |
Description | European Society of Medical Oncology Congress Abstract - Reducing the Frequency of Immune Checkpoint Inhibition in Cancer |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | A trials in progress abstract was presented 'REducing the Frequency of ImmuNE checkpoint inhibition in cancer' at the European Society of Medical Oncology Congress in September 2023 in Paris. |
Year(s) Of Engagement Activity | 2022 |
URL | https://oncologypro.esmo.org/meeting-resources/esmo-congress/reduced-frequency-immune-checkpoint-inh... |
Description | Focus Groups with people affected by melanoma and renal cell carcinoma |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | A series of focus groups were conducted with people affected by kidney cancer and melanoma in order to understand patient perspectives of reducing the intensity of immune checkpoint inhibition. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.mrcctu.ucl.ac.uk/studies/all-studies/r/refine/optic |
Description | Poster at Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Poster presented at conference - Exploring the disparity between mortality reduction and stage shift, treatment and survival from randomisation in High Grade Serous Ovarian Cancer in UKCTOCS |
Year(s) Of Engagement Activity | 2019 |
Description | Presentation on RADICALS for Prostate Cancer Support Organisation (PCaSO) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Online presentation by Chris Parker (Chief Investigator) on RADICALS trials results for Prostate Cancer Support Organisation (PCaSO) |
Year(s) Of Engagement Activity | 2023 |
URL | https://pcaso.org/zoom-event-2nd-march-on-radicals-hd/ |
Description | STAMPEDE M1RT infographic |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | This infographic summarises results from the M1RT comparison of the STAMPEDE trial. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.mrcctu.ucl.ac.uk/media/2108/full-infographic_stampede-m1-radiotherapy-comparison.png |
Description | STAMPEDE docetaxel M0 long-term follow-up infographic |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | This infographic summarises long-term results from the docetaxel comparison of the STAMPEDE trial. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.mrcctu.ucl.ac.uk/media/2147/infographic-stampede-docetaxel_2.png |
Description | TRISST Health Economics |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation of TRISST Health Economics at GU ASCO 2023 |
Year(s) Of Engagement Activity | 2023 |
URL | https://meetings.asco.org/abstracts-presentations/217707 |
Description | TRISST infographic |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | This infographic summarises key results from the TRISST trial. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.mrcctu.ucl.ac.uk/media/2065/trisst_infographic_final_v2.png |